Blueprint Medicines Corp

Blueprint Medicines — Corporate Update (June 2019)

21 slides from Blueprint Medicines's corporate update, Jun 17, 2019

  1. Slide 1: Living with advanced systemic mastocytosis: Avapritinib program update teleconference

    R.S. Living with advanced systemic mastocytosis Avapritinib program update teleconference Monday, June 17, 2019 blueprint TM MEDICINES

  2. Slide 2: Blueprint Medicines call agenda and participants

    Blueprint Medicines call agenda and participants Introduction Kristin Hodous, Senior Manager, Investor Relations Corporate update Jeff Albers, Chief Executive Officer Systemic mastocytosis data presented at 24th EHA Congress Andy Boral, MD, PhD, Chief Medical Officer Avapritinib program next steps J

  3. Slide 3: Forward-looking statements

    Forward-looking statements 3 This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project

  4. Slide 4: Avapritinib: potent and highly selective KIT and PDGFRA inhibitor

    3L GIST 4L GIST PDGFRA Exon 18 mutant GIST First new drug application for avapritinib submitted to FDA * Trial planned to initiate 2H 2019. Target GIST populations have unresectable or metastatic disease. Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc. (www.cellsignal.com)

  5. Slide 5: Avapritinib induces complete and durable responses in advanced systemic mastocytosis (EHA)

    Avapritinib, a Potent and Selective Inhibitor of KIT D816V, Induces Complete and Durable Responses in Patients with Advanced Systemic Mastocytosis European Hematology Association Annual Meeting Amsterdam, Netherlands, 15 June 2019 Deepti Radia, Michael W. Deininger, Jason Gotlib, Prithviraj Bose, Ma

  6. Slide 6: EXPLORER clinical trial design

    Phase 1 EXPLORER clinical trial design AdvSM AdvSM, mIWG-MRT-ECNM evaluable Cohort 1: 300 mg QD Cohort 2: 200 mg QD Part 1: Dose escalation (N=32) Part 2: Expansion (N=37) avapritinib 30-400 mg QD Key entry criteria: AdvSM (ASM, SM-AHN or MCL) or relapsed/refractory myeloid malignancy per local asse

  7. Slide 7: Central pathology and adjudication implemented

    Central pathology and adjudication implemented Central Assessments Central tryptase and imaging Central pathology and mutation assessment Central adjudication of diagnosis and response EXPLORER trial now performing central adjudication for confirmation of diagnosis and consistency of response evalua

  8. Slide 8: Patient baseline characteristics

    Parameter All patients (N=69) mIWG Evaluable* pts (N=39) Median age, years (range) / Female, n (%) 62 (34 – 83) / 33 (48) 66 (34 – 83) / 21 (54) SM subtype per central assessment, n (%)* AdvSM ASM SM-AHN MCL ISM or SSM Not SM (CMML) 53 (77) 7 (10) 37 (54) 9 (13) 15 (22) 1 (1) 39 (100) 3 (8) 28 (72)

  9. Slide 9: 65% of patients return to normal tryptase levels

    65% of patients return to normal tryptase levels ≥50% tryptase reduction in every patient treated normal serum tryptase is defined as <11.4ng/mL # < 20ng/mL is a criterion for complete remission per mIWG-MRT-ECNM 9 Serum Tryptase (central) Best Change from Baseline (%) 0 -20 -40 -60 -80 -100 >50% de

  10. Slide 10: 79% of patients clear marrow mast cell aggregates

    79% of patients clear marrow mast cell aggregates ≥50% marrow cells reduction in 93% of patients Only patients with MC aggregates at baseline who have post-baseline assessments included * Clearance of marrow MC aggregates, but necessarily interstitial MC, is a criterion for complete remission per mI

  11. Slide 11: 84% of palpable spleens become non-palpable

    84% of palpable spleens become non-palpable Only patients with measurable spleens at baseline who have post-baseline assessments included *Of 44 palpable spleens at baseline, 37 (84%) become non-palpable. One not shown on figure as no post-baseline scan yet ≥35% reduction in spleen volume in 81% of

  12. Slide 12: Summary of mast cell burden reductions

    64% of patients return to normal tryptase levels ≥50% tryptase reduction in every patient treated normal serum tryptase is defined as <11.4ng/mL # < 20ng/mL is a criterion for complete remission per mIWG-MRT-ECNM 79% of patients clear marrow mast cell aggregates ≥50% marrow cells reduction in 93% of

  13. Slide 13: High rate of confirmed mIWG-MRT-ECNM responses across AdvSM subtypes

    High rate of confirmed mIWG-MRT-ECNM responses across all AdvSM subtypes 1 CRh: Requires all criteria for CR be met and response duration must be ≥12 weeks (to be confirmed); however, patient may have residual cytopenias. The following are required for CRh: ANC > 0.5 × 109/L with normal differential

  14. Slide 14: Responses occur rapidly and deepen over time

    Responses occur rapidly and deepen over time Median time to initial response 2 months 74% of patients maintain response for at least 12 months Median time to CR/CRh is 16 months On therapy up to 34 months 14 *Only 3 pts met the mIWG-MRT-ECNM PD response criteria (all transformation to AML), however

  15. Slide 15: Median overall survival not reached for any subtype

    Median overall survival not reached for any subtype ISM/SSM + ASM MCL SM-AHN Subtype % All AdvSM 78 ASM 100 SM-AHN 70 MCL 88 ISM or SSM 100 Estimated 24 month OS rate 15 Only patients with a central diagnosis of SM shown (n=68) Overall Survival Probability (%) ASM SM-AHN MCL ISM/SSM Months from Firs

  16. Slide 16: Treatment-emergent adverse events

    Treatment-emergent adverse events (AEs) Adverse event, n (%) Any Grade Grade 3/4 Anemia 38 (55) 20 (29) Thrombocytopenia 24 (35) 16 (23) Neutropenia 8 (12) 7 (10) Periorbital edema 52 (75) 3 ( 4) Diarrhea 28 (41) 1 ( 1) Nausea 26 (38) 3 ( 4) Fatigue 25 (36) 5 ( 7) Peripheral Edema 23 (33) 0 Vomiting

  17. Slide 17: Avapritinib induces complete and durable responses across SM spectrum

    77% confirmed central ORR by mIWG-MRT-ECNM criteria in AdvSM Responses across all subtypes and poor prognosis S/A/R genotype Responses occur at a median time of 2 mos and deepen over time Dose escalation patients (even cohort 1) still on therapy up to 34 months KIT D816V eventually becomes undetecta

  18. Slide 18: ISM and SSM patients have deep reductions in mast cell burden

    ISM and SSM patients have deep reductions in mast cell burden 19 Best Change from Baseline (%) Serum Tryptase Marrow mast cells Spleen Volume Marrow KIT D816V n=15 n=13 n=15 n=10 >50% decrease in tryptase tryptase decreased to <20 ng/mL* tryptase normalized to < 11.4ng/mL >50% decrease in MC MC aggr

  19. Slide 19: Key avapritinib program next steps in systemic mastocytosis

    Key avapritinib program next steps in systemic mastocytosis Data presented at 24th EHA Congress in June 2019. Data cut-off date: January 2, 2019. Avapritinib granted Breakthrough Therapy Designation for the treatment of advanced SM, including the subtypes of aggressive SM, SM with an associated hema

  20. Slide 20: Rapidly advancing pipeline of investigational precision therapies

    DRUG CANDIDATE (TARGET) DISCOVERY EARLY CLINICAL DEVELOPMENT LATE CLINICAL DEVELOPMENT REGULATORY SUBMISSION APPROVED COMMERCIAL RIGHTS Avapritinib (KIT & PDGFRA) BLU-667 (RET) BLU-554 (FGFR4) BLU-782 (ALK2) 4 undisclosed targets Immunokinase targets Rapidly advancing pipeline of investigational pre

  21. Slide 21: Thank you

    Thank you blueprint TM MEDICINES

Blueprint Medicines — Corporate Update (June 2019) on 6ix